Strategic report Governance & remuneration Financial statements Investor information Group financial review continued Property, plant and equipment Financial position and resources Our business is science-based, technology-intensive and highly regulated by governmental authorities.
We allocate significant 2015 2014 m m financial resources to the renewal and maintenance of our property, Assets plant and equipment to minimise risks of interruption of production and to achieve compliance with regulatory standards.
A number Non-current assets of our processes use chemicals and hazardous materials.
Property, plant and equipment 9,668 9,052 Goodwill 5,162 3,724 The total cost of our property, plant and equipment at Other intangible assets 16,672 8,320 31 December 2015 was 20,750 million, with a net book value of 9,668 million.
Of this, land and buildings represented Investments in associates and joint ventures 207 340 4,117 million, plant and equipment 2,987 million and assets Other investments 1,255 1,114 in construction 2,564 million.
In 2015, we invested 2,134 million Deferred tax assets 2,905 2,688 in new property, plant and equipment.
This was mainly related Other non-current assets 990 735 to a large number of projects for the renewal, improvement Total non-current assets 36,859 25,973 and expansion of facilities at various worldwide sites.
Property is mainly held freehold.
New investment is nanced from our Current assets liquid resources.
At 31 December 2015, we had contractual Inventories 4,716 4,231 commitments for future capital expenditure of 659 million and Current tax recoverable 180 138 operating lease commitments of 789 million.
We believe that Trade and other receivables 5,615 4,600 our facilities are adequate for our current needs.
Derivative financial instruments 125 146 We observe stringent procedures and use specialist skills to Liquid investments 75 69 manage environmental risks from our activities.
Environmental Cash and cash equivalents 5,830 4,338 issues, sometimes dating from operations now modied or Assets held for sale 46 1,156 discontinued, are reported under Our planet on page 48 and in Note 45 to the financial statements, Legal proceedings.
Total current assets 16,587 14,678 Total assets 53,446 40,651 Goodwill Goodwill increased during the year to 5,162 million at Liabilities 31 December 2015, from 3,724 million.
The increase reected Current liabilities the goodwill arising from the acquired Novartis Vaccines business Short-term borrowings 1,308 2,943 and the creation of the Consumer Healthcare Joint Venture.
Trade and other payables 9,191 7,958 Other intangible assets Derivative financial instruments 153 404 Other intangible assets include the cost of intangibles acquired Current tax payable 1,421 945 from third parties and computer software.
The net book value Short-term provisions 1,344 1,045 of other intangible assets as at 31 December 2015 was Total current liabilities 13,417 13,295 16,672 million 2014 8,320 million.
The increase in 2015 reected the impact of acquiring the Vaccines business Non-current liabilities 2,680 million, and the creation of the Consumer Healthcare Long-term borrowings 15,324 15,841 Joint Venture 6,003 million, capitalised development costs of Deferred tax liabilities 1,522 445 217 million, partly offset by the amortisation and impairment of Pensions and other post-employment benets 3,229 3,179 existing intangibles of 738 million and 217 million, respectively.
Other provisions 420 545 Investments in associates and joint ventures Derivative financial instruments 9 We held investments in associates and joint ventures, with a Other non-current liabilities 10,656 2,401 carrying value at 31 December 2015 of 207 million 2014 Total non-current liabilities 31,151 22,420 340 million.
The market value at 31 December 2015 was 267 million 2014 1,388 million.
The largest of these Total liabilities 44,568 35,715 investments was in Theravance Inc. now Innoviva Inc. which had Net assets 8,878 4,936 a book value at 31 December 2015 of 112 million.
The market Equity value at 31 December 2015 was 229 million.
Until 1 September 2015, Theravance Inc. was accounted for as an equity investment Share capital 1,340 1,339 as it was considered that the Group could not exert significant Share premium account 2,831 2,759 inuence over the company until that point.
See Note 20 to the Retained earnings 1,397 2,074 Financial statements Investments in associates and joint ventures.
Other reserves 2,340 2,239 Other investments Shareholders equity 5,114 4,263 We held other investments with a carrying value at 31 December Non-controlling interests 3,764 673 2015 of 1,255 million 2014 1,114 million.
The most Total equity 8,878 4,936 significant of these investments was in Aspen Pharmacare Holdings Limited which had a book value at 31 December 2015 of 383 million.
Previously, the investment in Aspen was treated as an associate but in March 2015 we sold half of our holding in Aspen and as a result were no longer able to exert significant inuence over the company: the investment has been reported within Other investments since that date.
The other investments include equity stakes in companies with which we have research collaborations, which provide access to biotechnology developments of potential interest and interests in companies that arise from business divestments.
66 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Derivative financial instruments: assets Other non-current liabilities We had current derivative financial instruments held at fair value Other non-current liabilities of 10,656 million at 31 December of 125 million 2014 146 million.
The majority of this amount 2015 2014 2,401 million included 3,549 million related to foreign exchange contracts both designated and not 2014 1,619 million of contingent consideration payable, designated as accounting hedges.
of which 3,110 million 2014 1,579 million was in respect of the acquisition in 2012 of the former Shionogi-ViiV Healthcare joint Inventories venture, and 398 million was payable to Novartis in relation to Inventory of 4,716 million increased from 4,231 million in the Vaccines acquisition during 2015.
The increase primarily reected the impact of the Novartis related to the present value of the estimated amount payable by acquisition, partly offset by exchange movements.
us in the event of full exercise of Novartis right to require us to Trade and other receivables acquire its 36.5% shareholding in the Consumer Healthcare Trade and other receivables of 5,615 million increased from Joint Venture.
2014 impacted by the Novartis acquisition, partly offset by Net debt exchange movements.
2015 2014 Derivative financial instruments: liabilities m m We held current derivative financial instruments at fair value Cash, cash equivalents and liquid investments 5,905 4,407 of 153 million 2014 404 million, current: 9 million, nonBorrowings repayable within one year 1,308 2,943 current.
This primarily related to foreign exchange contracts both Borrowings repayable after one year 15,324 15,841 designated and non-designated inter-company loans and trade Net debt 10,727 14,377 receivables as accounting hedges.
At 31 December 2015, net debt was 10.7 billion, compared with Trade and other payables 14.4 billion at 31 December 2014, comprising gross debt of Trade and other payables amounting to 9,191 million increased 16.6 billion and cash and liquid investments of 5.9 billion.
The from 7,958 million in 2014, reecting the effect of the Novartis decrease in net debt primarily reected the impact of the Novartis acquisition and an increase in accruals for customer returns and transaction in which we sold our Oncology business for net cash rebates.
proceeds of 10.0 billion and paid 3.4 billion, net of cash Provisions acquired, to purchase the Novartis Vaccines business.
We carried deferred tax provisions and other short-term and The first tax payments on the Novartis transaction amounting to non-current provisions of 3,286 million at 31 December 2015 1,071 million have been made.
In addition, we sold part of our 2014 2,035 million of which 352 million 2014 520 shareholding in Aspen for cash proceeds of 564 million and million related to legal and other disputes and 816 million paid dividends to shareholders of 3,874 million.
Net debt also 2014 527 million related to the Operational Excellence reected an exchange loss on the translation of cash held by the provision.
Provision has been made for legal and other disputes, Groups Venezuelan subsidiaries.
indemnified disposal liabilities, employee related liabilities and the costs of restructuring programmes to the extent that at the Because of the continuing political and economic uncertainties balance sheet date a legal or constructive obligation existed and in Venezuela, at 31 December 2015, we changed the could be reliably estimated.
exchange rate used to translate our subsidiaries in Venezuela.
Up to that point, we applied one of the ofcial rates available Pensions and other post-employment benets of VEF 6.3 US$1.
At 31 December 2015, this was changed to We account for pension and other post-employment VEF 199.6 US$1 VEF 293.4 1.
This change had no significant arrangements in accordance with IAS 19.
The deficits, impact on the Group income statement, but gave rise to an net of surpluses before allowing for deferred taxation were exchange loss on translation of the cash held by the Venezuelan 1,584 million 2014 1,689 million on pension arrangements subsidiaries of 94 million.
and 1,387 million 2014 1,397 million on unfunded postemployment liabilities.
The decreases in the deficits were At 31 December 2015, our cash and liquid investments were held predominantly driven by higher discount rates that we used to as follows: discount the value of the liabilities, partly offset by an increase 2015 2014 in the UK ination rate together with net obligations acquired m m as a result of the Novartis transaction.
Bank balances and deposits 3,767 3,529 In December 2010, the UK scheme purchased an insurance US Treasury and Treasury repo contract that will guarantee payment of specified pensioner only money market funds 624 811 liabilities.
This contract was valued at 755 million at Liquidity funds 1,439 31 December 2015.
Government securities 75 67 5,905 4,407 Cash and liquid investments of 4.2 billion were held centrally at 31 December 2015.
GSK Annual Report 2015 67 Strategic report Governance & remuneration Financial statements Investor information Group financial review continued Maturity prole of gross debt m equivalent 3,000 2,500 2,000 1,500 1,000 500 0 2016 2017 2018 2019 2022 2023 2024 2025 2027 2033 2034 2038 2039 2042 2043 2045 GBP bonds EUR bonds USD bonds Other bank borrowings Leases The analysis of cash and gross debt after the effects of hedging Total equity is as follows.
At 31 December 2015, total equity had increased from 4,936 million at 31 December 2014 to 8,878 million.
2015 2014 The increase arose from the impact of both operating profits m m and business and asset disposal profits, partly offset by the Cash and liquid investments 5,905 4,407 remeasurement of the ViiV Healthcare contingent consideration Gross debt xed 16,129 17,674 and the dividends paid in the year.
oating 502 1,109 A summary of the movements in equity is set out below.
non-interest bearing 1 1 Net debt 10,727 14,377 2015 2014 m m Total equity at beginning of year 4,936 7,812 Movements in net debt Total comprehensive income for the year 7,885 1,081 Dividends to shareholders 3,874 3,843 2015 2014 m m Ordinary shares issued 73 167 Net debt at beginning of year 14,377 12,645 Gain on transfer of net assets Increase decrease in cash and bank overdrafts 1,503 1,287 into Consumer Healthcare JV 2,891 Increase decrease in liquid investments 2 1 Consumer Healthcare JV put option 6,204 Net increase in long-term loans 1,960 Loss on transfer of equity investment to Net repayment of short-term loans 2,412 1,709 investment in associate 229 Exchange movements 268 193 Changes in non-controlling interests 3,370 86 Other movements 1 Forward contract relating to non-controlling Net debt at end of year 10,727 14,377 interest 21 Shares purchased and cancelled or held as Treasury shares 238 Shares acquired by ESOP Trusts 99 95 Share-based incentive plans 356 326 Tax on share-based incentive plans 10 4 Distributions to non-controlling interests 237 205 Total equity at end of year 8,878 4,936 The gain on transfer of net assets into the Consumer Healthcare Joint Venture of 2,891 million reects the difference between the book value of the GSK Consumer Healthcare net assets contributed to the Joint Venture and the fair value applied as the consideration for the Novartis contributed assets.
The Consumer Healthcare Joint Venture put option of 6,204 million reects the recognition of the initial value of the liability on the Group balance sheet.
The changes in noncontrolling interest primarily reect the recognition of the Novartis share of the Consumer Healthcare Joint Venture.
68 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Share purchases We have entered into a number of research collaborations to In 2015, the Employee Share Ownership Plan ESOP develop new compounds with other pharmaceutical companies.
Trusts acquired 99 million of shares in GlaxoSmithKline plc The terms of these arrangements can include upfront fees, equity 2014 245 million.
Shares are held by the Trusts to satisfy investments, loans and commitments to fund specified levels of future exercises of options and awards under the Group share research.
In addition, we will often agree to make further payments option and award schemes.
A proportion of the shares held by if future milestones are achieved.
the Trusts are in respect of awards where the rules of the scheme As some of these agreements relate to compounds in the early require us to satisfy exercises through market purchases rather stages of development, the potential obligation to make milestone than the issue of new shares.
The shares held by the Trusts are payments will continue for a number of years if the compounds matched to options and awards granted.
move successfully through the development process.
Generally, At 31 December 2015, the ESOP Trusts held 30 million the closer the product is to marketing approval, the greater the 2014 53 million GSK shares against the future exercise probability of success.
The amounts shown above within of share options and share awards.
The carrying value of intangible assets represent the maximum that would be paid 75 million 2014 151 million has been deducted from if all milestones were achieved, and include 5.1 billion which other reserves.
The market value of these shares was relates to externalised projects in the discovery portfolio.
A number of new commitments were made in 2015 under licensing and other agreements, offset by amendments to During 2015, no shares were repurchased.
2015, we held 491.5 million shares as Treasury shares 2014 491.5 million shares, at a cost of 6,917 million In 2013, we reached an agreement with the trustees of the 2014 6,917 million, which has been deducted from UK pension schemes to make additional contributions over a retained earnings.
three year period, including in 2013, to eliminate the pension deficit identied at the 31 December 2011 actuarial funding The company does not expect to make any ordinary share valuation.
If the deficit persists, further contributions would be repurchases in 2016.
No ordinary shares were purchased in payable in the following four years depending on the level of deficit.
the period 1 January 2016 to 25 February 2016.
The table above includes this commitment but excludes the normal Commitments and contingent liabilities ongoing annual funding requirement in the UK of approximately Financial commitments are summarised in Note 40 to the financial 140 million.
For further information on pension obligations, see statements, Commitments.
Other contingent liabilities and Note 28 to the financial statements, Pensions and other postobligations in respect of short and long-term debt are set out employment benets.
in Note 32 to the financial statements, Contingent liabilities Contingent liabilities and Note 31 to the financial statements, Net debt.
The following table sets out contingent liabilities, comprising Amounts provided for pensions and post-retirement benets are discounted bills, performance guarantees, letters of credit and set out in Note 28 to the financial statements, Pensions and other other items arising in the normal course of business, and when post-employment benets.
Amounts provided for restructuring they are expected to expire.
programmes and legal, environmental and other disputes are set Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs out in Note 29 to the financial statements, Other provisions.
m m m m m Contractual obligations and commitments Guarantees 126 94 19 11 2 The following table sets out our contractual obligations and Other contingent liabilities 74 17 36 5 16 commitments at 31 December 2015 as they fall due for payment.
Total 200 111 55 16 18 Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs In the normal course of business, we have provided various m m m m m indemnification guarantees in respect of business disposals Loans 16,688 1,285 4,151 1,103 10,149 in which legal and other disputes have subsequently arisen.
Interest on loans 9,282 638 1,135 908 6,601 A provision is made where an outow of resources is considered Finance lease obligations 70 23 34 12 1 probable and a reliable estimate can be made of the likely outcome Finance lease charges 7 2 2 3 of the dispute and this is included in Note 29 to the financial statements, Other provisions.
Operating lease commitments 789 191 174 111 313 We provide for the outcome of tax, legal and other disputes when Intangible assets 6,264 339 783 1,294 3,848 an outow of resources is considered probable and a reliable Property, plant & equipment 502 425 76 1 estimate of the outow may be made.
At 31 December 2015, other than for those disputes where provision has been made, Investments 157 61 52 38 6 it was not possible to make a reliable estimate of the potential Purchase commitments 38 2 24 12 outow of funds that might be required to settle disputes where Pensions 340 85 170 85 the possibility of there being an outow was more than remote.
Other commitments 191 60 87 44 The ultimate liability for such matters may vary signicantly from Total 34,328 3,111 6,688 3,608 20,921 the amounts provided and is dependent upon the outcome of Commitments in respect of loans and future interest payable litigation proceedings and negotiations with the relevant tax on loans are disclosed before taking into account the effect authorities.
This is discussed further in Risk factors on pages of derivatives.
231 to 240 and Notes 14 and 45 to the financial statements, Taxation and Legal proceedings.
